Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Gains from Sales and Divestitures (2017 - 2023)

Rhythm Pharmaceuticals (RYTM) has disclosed Gains from Sales and Divestitures for 5 consecutive years, with $214837.0 as the latest value for Q4 2023.

  • Quarterly Gains from Sales and Divestitures rose 35.5% to $214837.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $214837.0 through Dec 2023, up 35.5% year-over-year, with the annual reading at $214837.0 for FY2023, 35.5% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2023 was $214837.0 at Rhythm Pharmaceuticals, up from $158546.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $214837.0 in Q4 2023, with the low at $27583.0 in Q4 2021.
  • Average Gains from Sales and Divestitures over 3 years is $133655.3, with a median of $158546.0 recorded in 2022.
  • The sharpest move saw Gains from Sales and Divestitures surged 474.8% in 2022, then soared 35.5% in 2023.
  • Over 3 years, Gains from Sales and Divestitures stood at $27583.0 in 2021, then soared by 474.8% to $158546.0 in 2022, then skyrocketed by 35.5% to $214837.0 in 2023.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods came in at $214837.0, $158546.0, and $27583.0 for Q4 2023, Q4 2022, and Q4 2021 respectively.